Venture Cafe – Farshid Guilak, PhD and Jeffrey R. Millman, PhD, Present: Designer Stem Cells: Genome Engineering and the Next Generation of Cell-Based Therapies.

June 20, 2019
12:00 am - 12:00 am
Venture Café St. Louis, 4240 Duncan Ave, St. Louis, MO 63110

Precision Medicine Thursdays at at Venture Café
Attendance is FREE.  Registration available at the event.


Farshid Guilak, PhD, Professor of Orthopaedic Surgery, Washington University in St. Louis, Director of Research, Shriners Hospitals for Children– St. Louis Shriners

Designer Stem Cells: Genome Engineering and the Next Generation of Cell-Based Therapies: Stem cells provide tremendous promise for the development of new therapies but their translation to clinical practice has been limited.  By combining recent advances in gene editing, synthetic biology, and tissue engineering, we have created new classes of “designer” cells that have prescribed sensory systems, as well as synthetic gene circuits that provide for self-regulating drug delivery or enhanced tissue repair.  We show how these stem cells can then be engineered into different tissues or organs for treating various diseases, particularly arthritis and associated musculoskeletal conditions.

Jeffrey Millman, PhD, Assistant Professor of Medicine and Biomedical Engineering, Washington University in St. Louis

Revolutionizing Diabetes Healthcare with Organoid Technology: Healthcare costs for treating diabetes is over $42 billion per year, much of which is the purchase of insulin that patients need daily. This seminar will discuss insulin-producing organoid technologies using stem cell biology and bioengineering as a revolutionary next generation treatment for patients.

View this post on Instagram

Video 2 of 2 with Dr. Jeffrey Millman #vencafstl #thursdaygathering

A post shared by Venture Café St. Louis (@venturecafestl) on

Dr. Millman’s slides

On the third Thursday of every month, ICTS Precision Medicine hosts a session featuring WashU faculty working in translational genomics/precision medicine areas. Talks are typically oriented toward biotechnology, diagnostics, informatics, start-ups and precision interventions based on medical genomics innovations.